The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 16, No. 16 August 16, 2010
(The next issue will be on September 1, 2010)
__________________________________________________________
TRIGGER is also available by RSS Feed:
http://feeds.feedburner.com/blogspot/glro
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
AUTHORS: Stephanie A. Smith, Sharon H. Choi, Rebecca Davis-Harrison, Jillian Huyck, John Boettcher, Chad M. Reinstra, and James H. Morrissey
TITLE: Polyphosphate exerts differential effects on blood clotting, depending on polymer size
JOURNAL: Blood
ABSTRACT: Polyphosphate, a linear polymer of inorganic phosphate, is secreted by activated platelets and accumulates in many infectious microorganisms. We recently showed that polyphosphate modulates the blood coagulation cascade at three steps: it triggers the contact pathway, it accelerates factor V activation, and it enhances fibrin polymerization. We now report that polyphosphate exerts differential effects on blood clotting depending on polymer length. Very long polymers (>500mers, such as those present in microorganisms) were required for optimal activation of the contact pathway, while shorter polymers (~100mers, similar to the polymer lengths released by platelets) were sufficient to accelerate factor V activation and abrogate the anticoagulant function of tissue factor pathway inhibitor. Optimal enhancement of fibrin clot turbidity by polyphosphate required >250mers. Pyrophosphate, which is also secreted by activated platelets, potently blocked polyphosphate-mediated enhancement of fibrin clot structure, suggesting that pyrophosphate is a novel regulator of fibrin function. In conclusion, polyphosphate of the size secreted by platelets is very efficient at accelerating blood clotting reactions but is less efficient at initiating them or at modulating clot structure. Microbial polyphosphate, which is highly procoagulant, may function in host responses to pathogens.
PREPRINT:
http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2010-01-266791v1
SUBMITTED BY: Jim Morrissey
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/10kih57W5b5iucWke6bPhfQ/
Al-Ruzzeh S and Navia JL (2010) Caution with the published database reviews analyzing the off-label use of recombinant activated factor VII (rFVIIa) in cardiac surgery. Transfus Apher Sci
http://www.ncbi.nlm.nih.gov/pubmed/20675193
Atkinson BT, Jasuja R, Chen V, Nandivada P, Furie B, and Furie BC (2010) Laser-induced endothelial cell activation supports fibrin formation. Blood
http://www.ncbi.nlm.nih.gov/pubmed/20675401
Biancofiore G, Bindi LM, Cioni R, Cicorelli A, and Filipponi F (2010) Recombinant activated factor VII for hemoperitoneum after transjugular intrahepatic portosystemic shunt. Blood Coagul Fibrinolysis 21:611
http://www.ncbi.nlm.nih.gov/pubmed/20703105
Bolliger D, Szlam F, Azran M, Koyama K, Levy JH, Molinaro RJ, and Tanaka KA (2010) The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg
http://www.ncbi.nlm.nih.gov/pubmed/20686004
Borissoff JI, Heeneman S, Kilinc E, Kassak P, Van Oerle R, et al. (2010) Early atherosclerosis exhibits an enhanced procoagulant state. Circulation
http://www.ncbi.nlm.nih.gov/pubmed/20697022
Bouchard BA, Mann KG, and Butenas S (2010) No evidence for tissue factor on platelets. Blood 116:854-855.
http://www.ncbi.nlm.nih.gov/pubmed/20688968
Christensen MC, Parr M, Tortella BJ, Malmgren J, Morris S, Rice T, and Holcomb JB (2010) Global differences in causes, management, and survival after severe trauma: The recombinant activated factor VII Phase 3 Trauma Trial. J Trauma 69:344-352.
http://www.ncbi.nlm.nih.gov/pubmed/20699743
Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, et al. (2010) hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer
http://www.ncbi.nlm.nih.gov/pubmed/20700124
Economou M, Papadopoulou E, Vagianou I, Farmaki E, Gompakis N, and Athanassiou-Metaxa M (2010) Haematuria in a young patient with severe haemophilia and inhibitor presence receiving prophylactic treatment with recombinant factor VIIa. Blood Coagul Fibrinolysis 21:611-613.
http://www.ncbi.nlm.nih.gov/pubmed/20703104
Goto M, Imura T, Inagaki A, Ogawa N, Yamaya H, Fujimori K, Kurokawa Y, and Satomi S (2010) The impact of ischemic stress on the quality of isolated pancreatic islets. Transplant Proc 42:2040-2042.
http://www.ncbi.nlm.nih.gov/pubmed/20692402
Herrera RN, Amaya EI, Perez Aguilar RC, Joo Turoni C, Maranon R, Berman SG, Luciardi HL, Coviello A, and Bruno MP (2010) Inflammatory and prothrombotic activation with conserved endothelial function in patients with chronic, asymptomatic Chagas disease. Clin Appl Thromb Hemost
http://www.ncbi.nlm.nih.gov/pubmed/20699256
Iorio A, Matino D, D'Amico R, and Makris M (2010) Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 8:CD004449
http://www.ncbi.nlm.nih.gov/pubmed/20687076
Johansson PI and Ostrowski SR (2010) Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. Drug Des Devel Ther 4:107-116.
http://www.ncbi.nlm.nih.gov/pubmed/20689697
Kim JE, Kim KJ, Ahn W, Han KS, and Kim HK (2010) Local anesthetics inhibit tissue factor expression in activated monocytes via inhibition of tissue factor mRNA synthesis. Clin Appl Thromb Hemost
http://www.ncbi.nlm.nih.gov/pubmed/20699252
Manly DA, Boles J, and Mackman N (2010) Role of tissue factor in venous thrombosis. Annu Rev Physiol
http://www.ncbi.nlm.nih.gov/pubmed/20690821
Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, et al. (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16:887-896.
http://www.ncbi.nlm.nih.gov/pubmed/20676107
McVey JH (2010) O tissue factor, where art thou? Blood 116:676-677.
http://www.ncbi.nlm.nih.gov/pubmed/20688964
Naumnik B, Rydzewska-Rosolowska A, and Mysliwiec M (2010) Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: A prospective crossover randomized study. Clin Appl Thromb Hemost
http://www.ncbi.nlm.nih.gov/pubmed/20682597
Nishimura N, Takai M, Yamamoto E, and Hasumi K (2010) Purpurin as a specific inhibitor of spermidine-induced autoactivation of the protease plasma hyaluronan-binding protein. Biol Pharm Bull 33:1430-1433.
http://www.ncbi.nlm.nih.gov/pubmed/20686243
Puetz J (2010) Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients. Drug Des Devel Ther 4:127-137.
http://www.ncbi.nlm.nih.gov/pubmed/20689699
Stampfli SF, Akhmedov A, Gebhard C, Lohmann C, Holy EW, Rozenberg I, Spescha R, Shi Y, Luscher TF, Tanner FC, and Camici GG (2010) Aging induces endothelial dysfunction while sparing arterial thrombosis. Arterioscler Thromb Vasc Biol
http://www.ncbi.nlm.nih.gov/pubmed/20689076
van den Berg YW and Versteeg HH (2010) Alternatively spliced tissue factor. A crippled protein in coagulation or a key player in non-haemostatic processes? Hamostaseologie 30:144-149.
http://www.ncbi.nlm.nih.gov/pubmed/20680231
Wade CE, Eastridge BJ, Jones JA, West SA, Spinella PC, Perkins JG, Dubick MA, Blackbourne LH, and Holcomb JB (2010) Use of recombinant factor VIIa in US military casualties for a five-Year period. J Trauma 69:353-359.
http://www.ncbi.nlm.nih.gov/pubmed/20699744
Wang Y, Zhou J, Zhang Y, Wang X, and Chen J (2010) Delivery of TFPI-2 using SonoVue and adenovirus results in the suppression of thrombosis and arterial re-stenosis. Exp Biol Med (Maywood)
http://www.ncbi.nlm.nih.gov/pubmed/20682602
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.
DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________
